

**AMENDMENTS TO THE CLAIMS**

1-20. (Canceled)

21. (Currently amended) A method for enhancing a ~~pre-existing immune response~~ human antigen presenting cell (APC)-mediated human cytotoxic T lymphocyte (CTL) response, comprising ~~contacting~~ stimulating an APC with an agonist anti-CD40 antibody, or binding fragment thereof, ~~with a human antigen presenting cell (APC) and contacting said human APC with a human T lymphocyte, wherein said antibody or binding fragment thereof binds to CD40 on said human APC without completely blocking binding of CD40L to CD40, wherein said anti-CD40 antibody or binding fragment is capable of blocking binding of CD40L on a human T lymphocyte to CD40 on a human APC by 16-88% and wherein said antibody is capable of enhancing synergistically enhances an APC-mediated human cytotoxic T lymphocyte response~~ CTL activation.

22. (Currently amended) The method of claim 21 ~~31~~, wherein the antigen presenting cell is a monocyte derived dendritic cell.

23. (Currently amended) The method of claim 21 ~~31~~, wherein the antibody is a monoclonal antibody or binding fragment thereof.

24. (Currently amended) The method of claim 21 ~~31~~ or ~~32~~, wherein the monoclonal antibody is a chimeric, humanized, human, ~~DEIMMUNISED~~<sup>TM</sup>, or a single chain antibody, or an antibody in which the potential T cell epitopes have been eliminated.

25-28. (Canceled)

29. (Currently amended) The method of claim 21 ~~31~~, further comprising administering IFN- $\gamma$ .

30. (Currently amended) The method of claim 21 ~~31~~, wherein the agonist anti-CD40 antibody is administered by injection.

31. (New) A method for enhancing an antigen-specific cytotoxic T cell (CTL) response, wherein said CTL is activated with a human antigen presenting cell (APC) and wherein said APC is stimulated via the CD40 receptor with an antibody or binding fragment thereof that binds to said receptor and blocks binding of CD40L to CD40 by 16-88%.
32. (New) A method for enhancing an antigen specific cytotoxic T cell (CTL) response according to claim 31, wherein said antibody or binding fragment thereof blocks binding of CD40L to CD40 by 16-25%.
33. (New) A monoclonal antibody or binding fragment thereof produced by a hybridoma with American Type Culture Collection (ATCC) deposit designation PTA-2993, PTA-2994, PTA-2995, PTA-2996, PTA-2997, PTA-2998, or PTA-2999.
34. (New) A hybridoma with American Type Culture Collection (ATCC) deposit designation PTA-2993, PTA-2994, PTA-2995, PTA-2996, PTA-2997, PTA-2998, or PTA-2999.
35. (New) The monoclonal antibody or fragment of claim 33, produced by the hybridoma with ATCC deposit designation PTA-2993.
36. (New) The hybridoma of claim 34 with ATCC deposit designation PTA-2993.
37. (New) The monoclonal antibody or fragment of claim 33, produced by the hybridoma with ATCC deposit designation PTA-2994.
38. (New) The hybridoma of claim 34 with ATCC deposit designation PTA-2994.
39. (New) The monoclonal antibody or fragment of claim 33, produced by the hybridoma with ATCC deposit designation PTA-2995.
40. (New) The hybridoma of claim 34 with ATCC deposit designation PTA-2995.

41. (New) The monoclonal antibody or fragment of claim 33, produced by the hybridoma with ATCC deposit designation PTA-2996.
42. (New) The hybridoma of claim 34 with ATCC deposit designation PTA-2996.
43. (New) The monoclonal antibody or fragment of claim 33, produced by the hybridoma with ATCC deposit designation PTA-2997.
44. (New) The hybridoma of claim 34 with ATCC deposit designation PTA-2997.
45. (New) The monoclonal antibody or fragment of claim 33, produced by the hybridoma with ATCC deposit designation PTA-2998.
46. (New) The hybridoma of claim 34 with ATCC deposit designation PTA-2998.
47. (New) The monoclonal antibody or fragment of claim 33, produced by the hybridoma with ATCC deposit designation PTA-2999.
48. (New) The hybridoma of claim 34 with ATCC deposit designation PTA-2999.